Ebglyss vs. Dupixent: A Detailed Comparison of Biologic Treatments for Atopic Dermatitis

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. For individuals living with moderate to severe forms of this condition, traditional treatments like topical corticosteroids and calcineurin inhibitors may not be sufficient. In recent years, biologic medications have revolutionized the management of AD, offering targeted therapies that address the underlying immune system dysfunction. Among these, Dupixent (dupilumab) has been a cornerstone, and more recently, Ebglyss (lebrikizumab) has emerged as a new option. This comprehensive guide will delve into Ebglyss and Dupixent, exploring their mechanisms of action, indications, efficacy, side effects, and key differences to help you understand which treatment might be suitable for you.

What is Atopic Dermatitis?

Atopic dermatitis is a complex, long-lasting skin condition that affects millions worldwide. It's part of the 'atopic triad,' which also includes asthma and allergic rhinitis (hay fever). The exact cause of AD is not fully understood, but it's believed to involve a combination of genetic predisposition, immune system dysfunction, and environmental factors.

Symptoms of Atopic Dermatitis

• Intense Itching (Pruritus): Often the most distressing symptom, leading to scratching that can worsen inflammation and skin damage.
• Dry Skin (Xerosis): The skin barrier is compromised, leading to moisture loss.
• Redness and Inflammation: Affected areas often appear red, especially in lighter skin tones, and can be swollen.
• Rashes: Can appear as patches of dry, scaly, thickened skin (lichenification), or small, raised bumps that may ooze and crust over.
• Location: In infants, it often appears on the face and scalp. In children and adults, it commonly affects the creases of the elbows and knees, neck, wrists, and ankles.
• Skin Infections: Due to scratching and compromised skin barrier, individuals with AD are more susceptible to bacterial, viral, and fungal infections.

Causes and Risk Factors

While the precise cause is unknown, several factors contribute to AD development:

• Genetics: A family history of eczema, asthma, or hay fever increases the risk.
• Immune System Dysfunction: An overactive immune response leads to inflammation. Key players include interleukins (IL-4, IL-13, IL-31), which are targeted by biologics.
• Skin Barrier Dysfunction: A defective skin barrier allows allergens, irritants, and microbes to penetrate more easily, triggering immune responses and moisture loss.
• Environmental Factors: Irritants like harsh soaps, detergents, certain fabrics, and allergens like pollen, dust mites, and pet dander can trigger or worsen flare-ups.
• Stress: Emotional stress can exacerbate symptoms.

Diagnosis of Atopic Dermatitis

Diagnosis is primarily clinical, based on a physical examination of the skin and a review of the patient's medical history and symptoms. There are no specific lab tests to diagnose AD, but a doctor might perform tests to rule out other skin conditions or identify potential allergens.

Understanding Biologic Medications for Atopic Dermatitis

Biologic drugs are a class of medications derived from living organisms, such as cells or proteins. Unlike traditional systemic treatments that broadly suppress the immune system, biologics target specific components of the immune response involved in disease pathways. For AD, this means targeting specific cytokines (signaling proteins) like interleukins that drive inflammation and itching.

Dupixent (Dupilumab): The Established Biologic

Dupixent was the first biologic approved for moderate to severe atopic dermatitis, marking a significant advancement in treatment options. It has been approved for use in adults and children as young as 6 months of age.

Mechanism of Action

Dupixent is a monoclonal antibody that works by blocking the signaling of two key proteins: interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are central to the type 2 inflammatory response, which is a major driver of atopic diseases like AD, asthma, and allergic rhinitis. By inhibiting both IL-4 and IL-13 pathways, Dupixent helps to reduce inflammation, improve skin barrier function, and alleviate itching.

Indications

Beyond moderate to severe atopic dermatitis, Dupixent is also approved for:

• Moderate to severe asthma
• Chronic rhinosinusitis with nasal polyps (CRSwNP)
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis

Dosage and Administration

Dupixent is administered via subcutaneous injection. For adults with atopic dermatitis, the typical dosing involves an initial loading dose followed by maintenance doses every two weeks. Dosing for children varies by age and weight.

Efficacy

Clinical trials have demonstrated Dupixent's significant efficacy in improving AD symptoms. Patients treated with Dupixent experienced:

• Significant reduction in itching (pruritus).
• Clearer skin, with many achieving Eczema Area and Severity Index (EASI) 75 or 90 (75% or 90% improvement in EASI score).
• Improved quality of life.
• Reduced need for topical corticosteroids.

Common Side Effects

While generally well-tolerated, common side effects of Dupixent can include:

• Injection site reactions (pain, redness, swelling)
• Conjunctivitis (pink eye) and other eye-related issues (e.g., dry eye, blepharitis)
• Oral herpes
• Eosinophilia (increased levels of eosinophils, a type of white blood cell)
• Mild cold symptoms (nasopharyngitis)

Rarely, serious allergic reactions can occur.

Ebglyss (Lebrikizumab): The Newer Contender

Ebglyss is a newer biologic medication that received FDA approval in December 2023 for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older weighing at least 40 kg.

Mechanism of Action

Ebglyss is also a monoclonal antibody, but it works by selectively targeting and inhibiting interleukin-13 (IL-13). Unlike Dupixent, which blocks both IL-4 and IL-13, Ebglyss focuses solely on IL-13. IL-13 plays a critical role in driving key aspects of AD pathophysiology, including skin barrier dysfunction, itching, and inflammation. By specifically blocking IL-13, Ebglyss aims to interrupt these disease processes.

Indications

Currently, Ebglyss is approved only for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (12 years and older, weighing at least 40 kg) who are candidates for systemic therapy.

Dosage and Administration

Ebglyss is administered via subcutaneous injection. The initial dosing involves a loading dose, followed by maintenance doses administered either every two weeks or every four weeks, depending on the patient's response and physician's assessment. The potential for a less frequent dosing schedule (every four weeks) for some patients is a notable feature.

Efficacy

Clinical trials for Ebglyss have shown robust efficacy similar to other biologics in the treatment of moderate-to-severe AD:

• Significant improvements in skin clearance (EASI 75 and EASI 90 scores).
• Rapid and sustained reduction in itching.
• Improvement in quality of life measures.

Common Side Effects

Common side effects reported with Ebglyss include:

• Injection site reactions
• Conjunctivitis
• Allergic conjunctivitis
• Oral herpes
• Other herpes viral infections

As with other biologics, serious allergic reactions are possible but rare.

Ebglyss vs. Dupixent: A Head-to-Head Comparison

While both Ebglyss and Dupixent are highly effective biologic treatments for moderate to severe atopic dermatitis, they have distinct characteristics that may influence treatment decisions.

Key Similarities

• Class: Both are monoclonal antibodies (biologics).
• Administration: Both are administered via subcutaneous injection.
• Target Condition: Both are highly effective for moderate-to-severe atopic dermatitis.
• Efficacy: Both have demonstrated significant improvements in skin clearance and reduction of itching in clinical trials.
• Common Side Effects: Share some common side effects, such as injection site reactions and conjunctivitis.

Key Differences

The primary distinctions lie in their mechanism of action, approved indications, and dosing frequency.

• Mechanism of Action:
  • Dupixent: Blocks both IL-4 and IL-13 pathways.
  • Ebglyss: Selectively blocks only the IL-13 pathway.

  This difference in targeting might lead to subtle variations in efficacy or side effect profiles for individual patients, though direct head-to-head comparative studies are limited.

• Approved Indications:
  • Dupixent: Has broader indications, including AD, asthma, CRSwNP, EoE, and prurigo nodularis.
  • Ebglyss: Currently approved only for moderate-to-severe AD.
• Dosing Frequency:
  • Dupixent: Typically administered every two weeks after an initial loading dose.
  • Ebglyss: Offers flexibility with maintenance dosing every two or four weeks for some patients after an initial loading dose, which might be a convenience factor for some individuals.
• Age Range:
  • Dupixent: Approved for AD in adults and children as young as 6 months.
  • Ebglyss: Approved for AD in adults and adolescents (12 years and older, weighing at least 40 kg).

Which One is Right for You?

The choice between Ebglyss and Dupixent is a highly individualized decision that should be made in consultation with a dermatologist. Factors that a healthcare provider will consider include:

• Severity of Atopic Dermatitis: Both are for moderate to severe cases.
• Patient Age: Dupixent has a broader age approval for pediatric patients.
• Presence of Co-existing Atopic Conditions: If a patient also has asthma or nasal polyps, Dupixent might be a more comprehensive option due to its broader indications.
• Previous Treatment History: Response to prior treatments, including other biologics, can guide future choices.
• Side Effect Profile: Tolerance to specific side effects (e.g., eye issues) might influence the choice.
• Dosing Convenience: The option of every four-week dosing with Ebglyss might be preferable for some patients.
• Patient Preference: Understanding patient concerns and preferences is crucial.

When to See a Doctor

If you or your child are experiencing symptoms of moderate to severe atopic dermatitis that are not well-controlled by topical treatments, it is crucial to consult a dermatologist. They can accurately diagnose your condition, discuss the full range of available treatments, and help determine if a biologic like Ebglyss or Dupixent is an appropriate option for you.

Prevention (Managing Atopic Dermatitis)

While biologics treat the underlying inflammation, managing atopic dermatitis also involves preventative measures and lifestyle adjustments:

• Moisturize Regularly: Apply thick, emollient creams or ointments daily, especially after bathing, to lock in moisture.
• Gentle Skin Care: Use mild, fragrance-free cleansers and avoid harsh soaps. Take lukewarm, short showers or baths.
• Identify and Avoid Triggers: Keep a symptom diary to identify potential irritants (e.g., certain fabrics, detergents, perfumes) and allergens (e.g., dust mites, pet dander, pollens).
• Wear Soft Fabrics: Opt for cotton clothing and avoid wool or synthetic materials that can irritate the skin.
• Manage Stress: Stress can exacerbate AD; incorporate stress-reduction techniques like meditation, yoga, or deep breathing.
• Avoid Scratching: Keep nails short, and consider wearing gloves at night to minimize skin damage from scratching.

Frequently Asked Questions (FAQs)

Are Ebglyss and Dupixent the same type of drug?

Both Ebglyss and Dupixent are biologic medications, specifically monoclonal antibodies. However, they differ in their precise mechanism of action: Dupixent targets both IL-4 and IL-13, while Ebglyss specifically targets IL-13.

Which biologic is more effective for atopic dermatitis?

Both Ebglyss and Dupixent have demonstrated high efficacy in clinical trials for treating moderate to severe atopic dermatitis. Direct head-to-head comparison studies are limited, making it difficult to definitively state one is 'more effective' than the other across all patients. The best choice often depends on individual patient factors, co-existing conditions, and physician assessment.

What are the main side effects of these medications?

Common side effects for both include injection site reactions and conjunctivitis (pink eye). Dupixent can also cause oral herpes and eosinophilia. Ebglyss may also cause other herpes viral infections. Your doctor will discuss the full side effect profile with you.

Can Ebglyss and Dupixent be used together?

No, Ebglyss and Dupixent are not typically used together as they target similar inflammatory pathways in atopic dermatitis. Using them concurrently would likely increase the risk of side effects without providing additional benefit.

How long do I need to take these medications?

Atopic dermatitis is a chronic condition, and biologic treatments like Ebglyss and Dupixent are typically prescribed for long-term use to maintain disease control. Your doctor will regularly assess your response to treatment and discuss the duration of therapy.

Conclusion

Ebglyss and Dupixent represent significant advancements in the treatment of moderate to severe atopic dermatitis. Dupixent, with its established track record and broader indications, targets both IL-4 and IL-13. Ebglyss, as a newer option, offers a targeted approach by specifically inhibiting IL-13 and may provide the convenience of less frequent dosing for some patients. The decision between these powerful biologics should always be made in close consultation with a dermatologist, who can weigh the specific needs, medical history, and co-existing conditions of each patient to determine the most appropriate and effective treatment plan.